Atrial fibrillation and obesity—results of a meta-analysis
To access this article, please choose from the options below
Dr Messerli served as an ad hoc consultant/speaker for the following organizations: Abbott, GSK, Novartis, Pfizer, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Forest, Sankyo, and Sanofi. Dr Somers is supported by grants HL 73211, HL 65176, and MO1-RR00585 from the National institutes of Health (Bethesda, MD). He serves as a consultant for Respironics, Cardiac Concepts, ResMed, and Sepracor.
This work was presented in part at the 2007 Annual Scientific Session of the American College of Cardiology, New Orleans, LA.
PII: S0002-8703(07)00783-1
doi:10.1016/j.ahj.2007.10.004
© 2008 Published by Elsevier Inc.
